Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Engelfriet

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Vox Sanguinis|June 26, 2003
The future use of pathogen-inactivated platelet concentratesC P Engelfriet, H W Reesink, H G Klein, et al.
Vox Sanguinis|August 20, 2003
Future counselling of donors and recipients of blood products concerning prion-related diseasesH W Reesink, C P Engelfriet, L Muylle, et al.
Vox Sanguinis|January 6, 2009
Neonatal transfusionsH V New, S J Stanworth, C P Engelfriet, et al.
Vox Sanguinis|January 14, 2009
Cord blood bankingA Brand, P Rebulla, C P Engelfriet, et al.
Vox Sanguinis|November 25, 2003
Current status of immunoprophylaxis with anti-D immunoglobinC P Engelfriet, H W Reesink, W J Judd, et al.
Vox Sanguinis|December 17, 2008
Genotyping for red blood cell polymorphismsC E van der Schoot, M de Haas, C P Engelfriet, et al.
Vox Sanguinis|August 25, 2001
Universal leucocyte-depletion of blood components: cell concentrates and plasmaC P Engelfriet, H W Reesink, R N Pietersz, et al.
Vox Sanguinis|September 12, 2007
Detection of bacterial contamination of platelet concentratesR N I Pietersz, C P Engelfriet, H W Reesink, et al.
Vox Sanguinis|February 24, 2001
Quality assurance, quality control and accreditationC P Engelfriet, H W Reesink, G G de Lange, et al.
Vox Sanguinis|December 12, 2007
Management of alloimmune thrombocytopeniaH H H Kanhai, L Porcelijn, C P Engelfriet, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Vox Sanguinis|June 26, 2003
The future use of pathogen-inactivated platelet concentratesC P Engelfriet, H W Reesink, H G Klein, et al.
Vox Sanguinis|August 20, 2003
Future counselling of donors and recipients of blood products concerning prion-related diseasesH W Reesink, C P Engelfriet, L Muylle, et al.
Vox Sanguinis|January 6, 2009
Neonatal transfusionsH V New, S J Stanworth, C P Engelfriet, et al.
Vox Sanguinis|January 14, 2009
Cord blood bankingA Brand, P Rebulla, C P Engelfriet, et al.
Vox Sanguinis|November 25, 2003
Current status of immunoprophylaxis with anti-D immunoglobinC P Engelfriet, H W Reesink, W J Judd, et al.
Vox Sanguinis|December 17, 2008
Genotyping for red blood cell polymorphismsC E van der Schoot, M de Haas, C P Engelfriet, et al.
Vox Sanguinis|August 25, 2001
Universal leucocyte-depletion of blood components: cell concentrates and plasmaC P Engelfriet, H W Reesink, R N Pietersz, et al.
Vox Sanguinis|September 12, 2007
Detection of bacterial contamination of platelet concentratesR N I Pietersz, C P Engelfriet, H W Reesink, et al.
Vox Sanguinis|February 24, 2001
Quality assurance, quality control and accreditationC P Engelfriet, H W Reesink, G G de Lange, et al.
Vox Sanguinis|December 12, 2007
Management of alloimmune thrombocytopeniaH H H Kanhai, L Porcelijn, C P Engelfriet, et al.
Pageof 17